Anti-human CEA MAb (Clone GFR44) RIA
Carcino-Embryonic Antigen is classified as a Tumor Marker.
In colorectal cancers, helps in determining stage and prognosis (significant correlation in the last two stages of Dukes' classification).
Assessment of therapeutic efficacy (post-surgery, chemotherapy or radiation treatment).
Indisputable indicator in the diagnosis of recurrences when deciding to perform early repeat surgery.
In breast and lung cancers, link between CEA levels and metastatic spread of the disease, constituting an element for assessment of a patient’s response to treatment.
In medullary thyroid cancer, the combination of CEA and thyrocalcitonin helps to confirm diagnosis and monitor relapses.
Our proprietary rat monoclonal antibody (IgG1) is used in IVD kits and for Research purposes.